Capitalizing on his clinical experinece, Dr. Kavros has made significant contributions to the medical device industry. After 9 years in private practice, he transitioned to the medical device industry for five years gaining significant business experience. He honed his skills in sales, marketing, product development, distribution and commercialization with Howmedica Orthopedics (Division of Pfizer), followed by Maryland Medical Laboratories, Inc. Following his two decade career at Mayo Clinic, he returned to the medical device industry.

• Product Manager - Howmedica Orthopedics (Pfizer, Inc): 1990-1992

  • Release of new trauma products for long bone fractures of the upper and lower extremities and maxillofacial surgery

  • Focused on sales and marketing in the New England region with responsibility of major hospital and academic institutions

• Vice President, Reference Testing - Maryland Medical Laboratories, Inc.: 1992 -1994

  • Managed clinical and anatomic testing to hospital systems in the mid Atlantic region of the United States

  • Responsible for growth and development of the reference testing market in the mid Atlantic region of the United States

  • Managed a sales force for direct sales and revenue growth.

  • Increase revenue from 16K/month to 165K/month in 16 months

• Medical Director - TEI Biosciences Inc. : 2012 - 2014

  • Medical oversight of the novel xenograft from neonatal bovine dermis for advanced tissue regeneration in acute and chronic wounds

  • Manage the continued validation of evidence based medicine through clinical trials

  • Direct responsibility for relationship building through key opinion leaders in the United States for adoption of PriMatrix

• Medical Director - Innovacyn, Inc.: 2014 - 2015

  • Medical oversight for the continued development and implementation of Hypochlorous solution in wound management

  • Focusing on the attribute of Hypochlorous solution’s positive clinical and economic affected on: wound bed management, biofilm control and improving healing times in acute and chronic wound

• Chief Medical Officer - Miromatrix Medical, Inc.: 2016 -2018

  • Medical oversight of a novel porcine liver xenograft produced from a unique manufacturing process, profusion decellularization.

  • Direct the education and implementation of a porcine xenograft to the sales staff

  • Manage the continued validation of evidence based medicine through clinical trials

  • Direct responsibility for key opinion leader relationship building in the United States for adoption of Miroderm.